Keiji Fukuda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6988381/publications.pdf

Version: 2024-02-01

70 20,797 40 68
papers citations h-index g-index

71 71 71 16205
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Building a multisystemic understanding of societal resilience to the COVID-19 pandemic. BMJ Global Health, 2021, 6, e006794.	2.0	20
2	Metagenomic Survey Reveals More Diverse and Abundant Antibiotic Resistance Genes in Municipal Wastewater Than Hospital Wastewater. Frontiers in Microbiology, 2021, 12, 712843.	1.5	6
3	Lessons From Influenza Pandemics of the Last 100 Years. Clinical Infectious Diseases, 2020, 70, 951-957.	2.9	57
4	Editorial: The Environmental Dimension of Antibiotic Resistance. FEMS Microbiology Ecology, 2020, 96,	1.3	23
5	National action to combat AMR: a One-Health approach to assess policy priorities in action plans. BMJ Global Health, 2020, 5, e002427.	2.0	22
6	Are high-performing health systems resilient against the COVID-19 epidemic?. Lancet, The, 2020, 395, 848-850.	6.3	386
7	Improving the estimation of the global burden of antimicrobial resistant infections. Lancet Infectious Diseases, The, 2019, 19, e392-e398.	4.6	68
8	Available evidence of antibiotic resistance from extended-spectrum \hat{I}^2 -lactamase-producing Enterobacteriaceae in paediatric patients in 20 countries: a systematic review and meta-analysis. Bulletin of the World Health Organization, 2019, 97, 486-501B.	1.5	22
9	Human infection with avian influenza A(H7N2) virus—Virginia, 2002. Influenza and Other Respiratory Viruses, 2018, 12, 529-532.	1.5	10
10	Impact of antibiotic stewardship programmes in Asia: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2018, 73, 844-851.	1.3	57
11	What is missing in surveillance for control of antimicrobial resistance?. Lancet Infectious Diseases, The, 2018, 18, 597-598.	4.6	3
12	Knowledge, Attitude, and Practice with Respect to Antibiotic Use among Chinese Medical Students: A Multicentre Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2018, 15, 1165.	1.2	45
13	Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC): Supporting the transition from strategy to action. Wellcome Open Research, 2018, 3, 59.	0.9	5
14	Building a global atlas of zoonotic viruses. Bulletin of the World Health Organization, 2018, 96, 292-294.	1.5	42
15	New mechanisms, new worries. Science, 2016, 351, 1263-1264.	6.0	44
16	Food safety in a globalized world. Bulletin of the World Health Organization, 2015, 93, 212-212.	1.5	47
17	Ebola Virus Disease in West Africa â€" The First 9 Months of the Epidemic and Forward Projections. New England Journal of Medicine, 2014, 371, 1481-1495.	13.9	1,367
18	Nonpharmaceutical Interventions for Pandemic Influenza, National and Community Measures. Emerging Infectious Diseases, 2012, 12, 88-94.	2.0	334

#	Article	lF	CITATIONS
19	Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: Basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere season. Vaccine, 2010, 28, 1156-1167.	1.7	145
20	Avian Influenza A (H5N1) Virus and 2 Fundamental Questions. Journal of Infectious Diseases, 2009, 199, 1717-1719.	1.9	8
21	The pandemic influenza vaccine challenge. Vaccine, 2008, 26, D3-D4.	1.7	11
22	WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infectious Diseases, The, 2007, 7, 21-31.	4.6	165
23	Nonpharmaceutical Interventions for Pandemic Influenza, International Measures. Emerging Infectious Diseases, 2006, 12, 81-87.	2.0	288
24	Health Benefits, Risks, and Cost-Effectiveness of Influenza Vaccination of Children. Emerging Infectious Diseases, 2006, 12, 1548-1558.	2.0	96
25	Different Approaches to Influenza Vaccination. New England Journal of Medicine, 2006, 355, 2586-2587.	13.9	11
26	Influenza-Associated Deaths among Children in the United States, 2003–2004. New England Journal of Medicine, 2005, 353, 2559-2567.	13.9	564
27	Influenza Vaccination Among the Elderly in the United States. Archives of Internal Medicine, 2005, 165, 2038.	4.3	11
28	An economic analysis of annual influenza vaccination of children. Vaccine, 2005, 23, 1004-1014.	1.7	85
29	Values for preventing influenza-related morbidity and vaccine adverse events in children. Health and Quality of Life Outcomes, 2005, 3, 18.	1.0	48
30	Influenza-Associated Hospitalizations in the United States. JAMA - Journal of the American Medical Association, 2004, 292, 1333.	3.8	1,892
31	Influenza in Thailand: a case study for middle income countries. Vaccine, 2004, 23, 182-187.	1.7	39
32	Age-specific estimates of US influenza-associated deaths and hospitalizations. International Congress Series, 2004, 1263, 316-320.	0.2	2
33	Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports, 2004, 53, 1-40.	26.7	181
34	Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States. JAMA - Journal of the American Medical Association, 2003, 289, 179.	3.8	3,197
35	Large Summertime Influenza A Outbreak among Tourists in Alaska and the Yukon Territory. Clinical Infectious Diseases, 2003, 36, 1095-1102.	2.9	67
36	Impact of influenza on young children and the shaping of United States influenza vaccine policy. Pediatric Infectious Disease Journal, 2003, 22, S231-S235.	1.1	23

#	Article	IF	CITATIONS
37	Acyclovir-Resistant Genital Herpes Among Persons Attending Sexually Transmitted Disease and Human Immunodeficiency Virus Clinics. Archives of Internal Medicine, 2003, 163, 76.	4.3	147
38	Risk of Influenza A (H5N1) Infection among Poultry Workers, Hong Kong, 1997–1998. Journal of Infectious Diseases, 2002, 185, 1005-1010.	1.9	237
39	Influenza Surveillance with Rapid Diagnostic Tests. Clinical Infectious Diseases, 2002, 34, 1422-1422.	2.9	2
40	Preparing for pandemic influenza: the need for enhanced surveillance. Vaccine, 2002, 20, S63-S65.	1.7	13
41	Influenza. Clinics in Laboratory Medicine, 2002, 22, 863-882.	0.7	5
42	Medical Care Capacity for Influenza Outbreaks, Los Angeles. Emerging Infectious Diseases, 2002, 8, 569-574.	2.0	70
43	Lack of Evidence for Human-to-Human Transmission of Avian Influenza A (H9N2) Viruses in Hong Kong, China 1999. Emerging Infectious Diseases, 2002, 8, 154-159.	2.0	85
44	Alternative models for estimating influenza-attributable P&I deaths in the US. International Congress Series, 2001, 1219, 33-36.	0.2	2
45	Influenza present: the impact of the 1999–2000 epidemic on morbidity and mortality in the USA. International Congress Series, 2001, 1219, 37-42.	0.2	0
46	Influenza A among Patients with Human Immunodeficiency Virus: An Outbreak of Infection at a Residential Facility in New York City. Clinical Infectious Diseases, 2001, 32, 1784-1791.	2.9	106
47	Vaccinating Japanese Schoolchildren against Influenza. New England Journal of Medicine, 2001, 344, 1946-1948.	13.9	15
48	Influenza Outbreak Detection and Control Measures in Nursing Homes in the United States. Journal of the American Geriatrics Society, 2000, 48, 1310-1315.	1.3	39
49	Effectiveness and Cost-Benefit of Influenza Vaccination of Healthy Working Adults. JAMA - Journal of the American Medical Association, 2000, 284, 1655.	3.8	589
50	Risk of Influenza A (H5N1) Infection among Health Care Workers Exposed to Patients with Influenza A (H5N1), Hong Kong. Journal of Infectious Diseases, 2000, 181, 344-348.	1.9	214
51	The Impact of Influenza Epidemics on Hospitalizations. Journal of Infectious Diseases, 2000, 181, 831-837.	1.9	431
52	Influenza and the Rates of Hospitalization for Respiratory Disease among Infants and Young Children. New England Journal of Medicine, 2000, 342, 232-239.	13.9	956
53	Preparing for Pandemic Influenza: The Need for Enhanced Surveillance. Emerging Infectious Diseases, 1999, 5, 297-299.	2.0	30
54	The Economic Impact of Pandemic Influenza in the United States: Priorities for Intervention. Emerging Infectious Diseases, 1999, 5, 659-671.	2.0	569

#	Article	IF	CITATIONS
55	Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays. Journal of Clinical Microbiology, 1999, 37, 937-943.	1.8	753
56	Antibody Response in Individuals Infected with Avian Influenza A (H5N1) Viruses and Detection of Antiâ∈H5 Antibody among Household and Social Contacts. Journal of Infectious Diseases, 1999, 180, 1763-1770.	1.9	221
57	Caseâ€Control Study of Risk Factors for Avian Influenza A (H5N1) Disease, Hong Kong, 1997. Journal of Infectious Diseases, 1999, 180, 505-508.	1.9	241
58	INFLUENZA. Infectious Disease Clinics of North America, 1998, 12, 27-38.	1.9	58
59	The epidemiology of chronic fatigue in San Francisco. American Journal of Medicine, 1998, 105, 83S-90S.	0.6	167
60	Characterization of an Avian Influenza A (H5N1) Virus Isolated from a Child with a Fatal Respiratory Illness. Science, 1998, 279, 393-396.	6.0	1,267
61	Chronic Multisymptom Illness Affecting Air Force Veterans of the Gulf War. JAMA - Journal of the American Medical Association, 1998, 280, 981.	3.8	613
62	An epidemiologic study of fatigue with relevance for the chronic fatigue syndrome. Journal of Psychiatric Research, 1997, 31, 19-29.	1.5	72
63	Fatiguing illness among employees in three large state office buildings, California, 1993: Was there an outbreak?. Journal of Psychiatric Research, 1997, 31, 31-43.	1.5	24
64	Development of the 1994 Chronic Fatigue Syndrome Case Definition and Clinical Evaluation Guidelines. , 1997, , 29-50.		1
65	Risk Factors for Chronic Fatigue Syndrome. The Journal of Chronic Fatigue Syndrome: Multidisciplinary Innovations in Researchory and Clinical Practice, 1996, 2, 17-33.	0.4	21
66	The Chronic Fatigue Syndrome. The Journal of Chronic Fatigue Syndrome: Multidisciplinary Innovations in Researchory and Clinical Practice, 1995, 1, 67-84.	0.4	12
67	The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study. Annals of Internal Medicine, 1994, 121, 953.	2.0	4,309
68	Guidelines for counseling human T-lymphotropic virus type I (HTLV-I)- and HTLV type II-infected persons. Transfusion, 1993, 33, 694-694.	0.8	9
69	Detection of HTLV-II in breastmilk of HTLV-II infected mothers. Lancet, The, 1992, 340, 1157-1158.	6.3	48
70	Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC): Supporting the transition from strategy to action. Wellcome Open Research, 0, 3, 59.	0.9	2